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Receptors
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Abstract
Receptor is a dynamic instrumental surface protein that helps to interact with 
specific molecules to respond accordingly. Platelet is the smallest in size among 
the blood components, but it plays many pivotal roles to maintain hemostasis 
involving its surface receptors. It (platelet) has cell adhesion receptors (e.g., inte-
grins and glycoproteins), leucine-rich repeats receptors (e.g., TLRs, glycoprotein 
complex, and MMPs), selectins (e.g., CLEC, P-selectin, and CD), tetraspanins 
(e.g., CD and LAMP), transmembrane receptors (e.g., purinergic—P2Y and 
P2X1), prostaglandin receptors (e.g., TxA2, PGH2, and PGI2), immunoglobulin 
superfamily receptors (e.g., FcRγ and FcεR), etc. on its surface. The platelet 
receptors (e.g., glycoproteins, protease-activated receptors, and GPCRs) during 
platelet activation are over expressed and their granule contents are secreted 
(including neurotransmitters, cytokines, and chemokines) into circulation, which 
are found to be correlated with different physiological conditions. Interestingly, 
platelets promote metastasis through circulation protecting from cytolysis and 
endogenous immune surveillance involving several platelets receptors. The 
updated knowledge about different types of platelet receptors in all probable 
aspects, including their inter- and intra-signaling mechanisms, are discussed with 
respect to not only its (platelets) receptor type but also under different patho-
physiological conditions.
Keywords: platelet receptors, thrombus, cancer, aging, cardiovascular disease, viral 
infection
1. Introduction
Platelets including other blood components were first time drawn by George 
Gulliver in 1841 (though it was not named platelet at that time) when he was work-
ing with a newly made compound microscope with twin lens [1]. Giulio Bizzozero 
at the end of the nineteenth century [2] first time coined the term and identified as 
platelets. Blood platelet in its form is found in mammals, but in birds and amphib-
ians, it is present in circulation as intact mononuclear thrombocytes [3]. Platelets 
are not true cells, and it is classified as cell fragments (from megakaryocyte by the 
megakaryocytopoiesis) having no nucleus inside. Platelets circulate in the blood-
stream and remain alive for 7–10 days. They (platelets) principally survey the inner 
lining of blood vessels. If they detect any breaches, they seal them in the vascu-
lature by the creation of thrombi [4]. Platelets generally remain in inactive state 
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Sl. 
no.
Classes of 
receptors
Types of 
receptors
Family Ligands Involvement References
1. GP GPIb-IX-V 
complex
Type I 
membrane 
spanning GP 
and leucine-rich 
repeat
vWF, 
thrombin, 
P-selectin, 
αMβ2, and 
Mac-1
Initiation 
of platelet 
recruitment
[5–22]
GPVI Immunoglobulin 
(Ig)
Collagen and 
laminin
Platelet 
aggregation
[23–26]
GPVI-FcRγ Transmembrane Collagen and 
laminin
Adhesion 
with collagen
[7, 27, 28]
Integrins 
(αIIbβ3, 
αvβ3, α2β1, 
α5β1, and 
α6β1)
Transmembrane Fibrinogen 
or vWF, 
vitronectin, 
collagen, 
fibronectin, 
and laminin, 
respectively
Platelet 
aggregations
[7, 29–35]
2. C-type lectin 
receptor
CLEC-2 Type II 
membrane 
protein C-type 
lectin receptor
Podoplanin 
and rhodocytin
Platelet 
aggregation
[36, 37]
3. Throm boxane TP  
(α and β)
Transmembrane 
and GPCR
TXA2 Platelet 
aggregation
[38–40]
4. Prostaglandin 
(PG)
PGE2 and 
PGI2
GPCR PG Aggregation 
as well as 
inhibition of 
aggregation
[41–45]
5. Thrombin PAR-1  
and -4
Transmembrane Thrombin Adhesion, 
spreading, 
and secretion
[19, 46]
6. Ephrin  
kinase
EphA  
and EphB
Tyrosine kinase Ephrins Inhibition in 
aggregation
[47, 48]
7. Purinergic P2Y1 and 
P2Y12
Transmembrane 
and GPCR
ADP Amplification 
of aggregation
[49–51]
P2X1 ATP
8. TAM TAM TAM tyrosine 
kinase
Gas6 Stabilization 
of aggregation
[7, 52, 53]
9. Tetraspanin CD151 Tetraspanin Fibrinogen Aggregation, 
stabilization 
of aggregates
[7, 54–65]
TSSC6 Not known
TLT-1 Not known
CD36 vWF, oxPL, 
TSP1, and 
oxLDL
PEAR1 FcεR1α
10. P-selectin P-selectin Selectin PSGL-1 Clot 
formation 
with 
leukocytes
[7, 65]
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and get activated only when a blood vessel is damaged. But hemostasis or blood 
coagulation is not the sole function of platelets; rather, it is employed in several 
multifunctional attributes monitoring the homeostasis of the body. The advance-
ment of understanding of platelet pathology has leaded scientists to go through 
the receptors for its instrumental role in different pathological conditions. There 
are 16 different classes of platelet receptors. Each class of some of these receptors 
has subtypes (Table 1). Platelet receptors (Figure 1), the surface proteins, are at 
the forefront of the recent research, and major advances have been made in under-
standing their molecular functions as well as their downstream signaling pathways. 
The experimental strategies with pharmacological inhibition and knocking out 
Sl. 
no.
Classes of 
receptors
Types of 
receptors
Family Ligands Involvement References
11. ITIM PECAM-1 Transmembrane 
and Ig
PECAM Inhibition 
in thrombus 
formation
[66–68]
G6b-B Transmembrane 
and Ig
HS Platelet 
production 
and activation
VPAC1 Transmembrane 
and Ig
PACAP Inhibition 
in platelet 
activation
12. TLR TLR-1, -2, 
-3, and -4
Lipoprotein Peptidoglycan 
and pathogen
Inflammatory 
response
[69–72]
13. Serotonin 
(5-HT)
5-HT 2A 
and 5-HT3
Transmembrane Serotonin Thrombus 
formation, 
vasodilation
[72–76]
14. Leucine-rich 
receptors
GPIb-IX-V 
complex
Transmembrane 
and Ig
vWF, 
thrombin, 
P-selectin, 
αMβ2, and 
Mac-1
Initiation 
of platelet 
recruitment
[5–22, 
69–72]
TLRs Lipoprotein Peptidoglycan 
and pathogen
Inflammatory 
response
15. Complement 
receptors
CR2, 
CR3, CR4, 
C3aR, 
C5aR, 
gC1qR, 
and cC1qR
Complement Pathogens Antimicrobial 
host defense
[69, 77]
16. DC-SIGN DC-SIGN Non-integrin Viral 
pathogens
Binding 
platelet 
with viral 
pathogens
[69, 78]
GP: glycoprotein; vWF: von Willebrand factor; TP: TXA2/PGH2 receptor; CLEC-2: C-type lectin-like type II 
transmembrane receptor; GPCR: G protein-coupled receptor; TX: thromboxane; PAR: protease-activated receptors; 
Eph: ephrin; TAM: Tyro 3, Axl, and Mer; TSSC6: tumor suppressing STF cDNA 6; Gas: growth arrest specific; TLT: 
TREM-like transcript-1; PEAR: platelet endothelial aggregation receptor-1; PECAM-1: platelet endothelial cell 
adhesion molecule; VPAC1: vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1; 
PACAP: pituitary adenylate cyclase-activating polypeptide; TLR: Toll-like receptor; 5-HT: 5-hydroxytryptamine, 
serotonin; DC-SIGN: dendritic cell-specific ICAM3-grabbing non-integrin.
Table 1. 
Classes of platelet receptors and their involvement in the maintenance of physiological hemostasis.
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of nearly all known receptors and many signaling molecules have helped to reveal 
new mechanisms for how the thrombotic and hemorrhagic propensity of platelets 
is controlled in health and disease [79]. The firm adhesion of platelets to the injury 
site forms first a monolayer. This monolayer acts like a reactive site for other free 
moving platelets to replenish further. The accumulation of platelets is found to 
depend on vWF and fibrinogen that act like cross-linking adjacent to the platelets 
and promotes a stable aggregated platelets or clot [80, 81]. This process is essential 
for the formation of primary hemostatic clot and also for the development of patho-
logical thrombi at site ruptured [82]. Further activation in developing thrombus 
converts platelets to a procoagulant phenotype, from a proaggregatory phenotype, 
which enables the assembly of the coagulation reaction complexes (the tenase and 
prothrombinase complex) on the platelet surface, necessary for thrombin and fibrin 
generation. These fibrins form a fibrin network and trap the RBCs and convert the 
white thrombus to the red clot [83]. This supports secondary hemostasis or red clot 
[83]. However, physiological thrombus formations or mural thrombi are found to 
be tightly regulated to avoid the excessive platelet accumulation at the site of injury. 
The vascular obstructions that are the principal pathological processes, to some 
extent, cause heart attacks and/or ischemic stroke as well [84]. During initiation, 
progression, and termination of this physiological thrombus formation, several 
receptors of platelet get involved as soon as the damage on the blood vessel wall 
happens. There are different surface receptors on the platelet which are involved not 
only in blood coagulation process but also in other immunogenic and/or pathogenic 
responses, even in neurodegeneration. In this chapter, the molecular aspects of 
different classes of platelet receptors and their contribution in different pathophysi-
ological conditions are discussed.
2. Glycoprotein (GP) receptors
On the membrane of platelet, a class of glycoprotein (GP) receptors is present 
which plays a key role in hemostasis. In fact, the blood vessel wall damage initiates 
the event of interaction of GP receptors with the extracellular matrix (Figure 1).
Figure 1. 
Different predominant platelet receptors and their physiological role. DC-SIGN: dendritic cell-specific ICAM3-
grabbing non-integrin; 5-HT: 5-hydroxytryptamine, serotonin. Other receptor details are same as described in 
the legends of Table 1.
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The GP receptors include:
• GPIb-IX-V complex,
• GPVI,
• GPVI-FcRγ, and
• integrins.
2.1 GPIb-IX-V complex
The GPIb-IX-V complex consists of glycoproteins (GP) Ibα, Ibβ, IX, and V, 
which are known as GPIbα (~135 kDa), GPIbβ (~25 kDa), GPIX (~20 kDa), and 
GPV (~85 kDa), respectively. The GPIbα is linked with a disulfide bond to GPIbβ 
and non-covalently associated with GPIX and GPV in a ratio of 2:2:2:1 [5, 6]. 
GPIbα, GPIbβ, and IX are present at almost 25,000 copies per platelet, whereas 
GPV at 12,500 copies which can be calculated easily by their abundance ratio in 
a complex. GPIbα, GPIbβ, and GPIX are found to be closely associated and the 
arrangements of these subunits are essential for an efficient bioavailability of GPIb 
to its ligand. Lack of any of the single subunits is significantly able to decrease the 
surface expression of the whole complex (GPIb), whereas GPV is more loosely 
associated with the complex and its absence does not interfere with the expres-
sion of GPIb as well as its interaction with its ligand, vWF. GPV has been found to 
be active only during the binding of thrombin to GPIbα subunit. It (complex) is 
found to be assembled in the megakaryocyte in the bone marrow (the origin site 
of platelet) as a functional unit [7]. These are type I membrane spanning GP and 
are members of the leucine-rich repeat family, with one or more approximately 
24-residue leucine-rich repeats, with their N- and C-terminal disulfide-looped 
flanking sequences, in their extracellular domains [5]. The four subunits are 
encoded by genes mapping to chromosomes 17p12 (GPIBA), 22q11.2 (GPIBB), 
3q29 (GP5), and 3q21 (GP9) [7]. GPIbα, the major ligand-binding subunit, has 
a globular N-terminal ligand-binding domain elevated from the cell surface by 
a sialomucin core [5]. This N terminal (282 residues) contains the leucine-rich 
repeats (LRR), the flanking sequences, and an anionic sequence (residues 269–282) 
with the sulfation (Tyr 276–279, except 277). The 1–282 sequence contains overlap-
ping, but distinct binding sites for (a) vWF, (b) leukocyte integrin αMβ2, and (c) 
P-selectin, a granule-membrane receptor expressed on the surface of activated 
platelets or activated endothelial cells [5, 8, 9]. The adhesion of vWF to GPIbα 
under shear stress involves electrostatic interactions between a negative patch 
(centered on residues 59–128) within the leucine-rich repeats of GPIbα and a 
complementary positive patch (centered on residues 496–709) on the vWF-A1 
domain [5, 10, 11]. The residues of N- and C-terminal to this region directly 
contact vWF in a co-crystal structure of a GPIbα fragment which lacks N-linked 
glycosylation sites at Asn21 and Asn159 [12]. The point mutations in either GPIbα 
(Met239/Val) or vWF-A1 (Arg543/Gln) alter their conformation producing subtle 
differences in their ligation as gain of function [12, 13]. More preciously, in the case 
of vWF-A1, the mutation is 415A from a GPIbα contacting sequence, emphasizing 
the sensitivity of interaction to the conformational regulations [12]. The gain-of-
function mutation at Arg543/Gln and Met239/Val enhances affinity for GPIbα by 
virtue of almost 6-fold. The Met239/Val gain-of-function mutation of GPIbα is 
within a b-hairpin structure in the C-terminal flank, which undergoes significant 
structural alteration in a complex with vWF-A1. This Met239/Val gain-of-function 
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mutation stabilizes the β-hairpin and increases the affinity of vWF binding [12]. 
These conformational changes of native GPIbα and vWF with isolated ligand and 
receptor fragments might regulate the affinity of the adhesive interaction and 
result in an on-rate/off-rate for platelet adhesion in either rolling or firm adhesion 
in flowing blood, though the in vivo study is still under progress to understand. 
Thrombin binding to GPIbα subunit presents the thrombin to its receptor, the 
protease activated receptor 1 (PAR-1). GPV acts as a negative modulator (as GPV 
cleaves by thrombin) of thrombin-induced platelet activation, which unmasks 
GPIb-IX complex and facilitates the binding of thrombin to GPIbα [13]. GPIb 
interacts with vascular P-selectin, pointing to its function in inflammatory platelet 
pathways [9]. Depending on the orientation of the active site on GPIbα-bound 
thrombin, thrombin-mediated proteolysis of platelet surface substrates (including 
GPV or PAR-1) may be regulated by interaction with GPIbα. GPIbα is a cofactor for 
PAR-1 activation [9]. In turn, thrombin can regulate GPIb-IX-V signaling directly 
by engagement of GPIbα under conditions where GPV is absent [9–15]. GPIbα-
associated thrombin also regulates Factor XI; the latter also binds to GPIbα [16]. 
The extracellular domain comprises the binding site for vWF, P-selectin, and Mac-1 
(Table 1). In addition to its dynamic role in platelet recruitment onto vWF, the 
GPIb membrane complex functions as a receptor for coagulation factor XII [17], XI 
[18], thrombin [19, 20], and HK (high-molecular-weight kininogen) [21]. Hence, 
GPIb is a receptor linking primary and secondary hemostasis [7]. The Src and Lyn 
of the Src family kinases (SFKs) are associated with the GPIbα subunit to initiate 
the inside-out signaling. Binding of vWF to the extracellular region of GPIbα sub-
unit induces SFK activation and phosphorylation of downstream substrates. These 
include immunoreceptor tyrosine-based activation motif (ITAM)-containing FcR 
γ-chain (FcRγ) and FcγRIIA. Both of them are found to be acted as high-affinity 
docking sites for the tandem SH2 domain-containing protein-tyrosine kinase Syk. 
Fc receptors (FcRγ chain and FcγRIIA) may also be associated with GPIb-IX-V on 
platelets and contribute to GPIb-IX-V-dependent platelet activation. Intracellular 
signals emanates from GPIb-IX-V [5, 6, 11, 22]. It promotes elevation of cytosolic 
Ca2+, cytoskeletal changes, secretion of agonists such as ADP (that activates G 
protein-coupled receptors, P2Y1 and P2Y12), and activation of the integrin αIIbβ3 
that binds vWF or fibrinogen and mediates platelet aggregation. In vivo, plasma 
vWF is not recognized by GPIb-IX-V on resting platelets, thus preventing platelet 
aggregation in the normal circulation, with the interaction being triggered when 
sub-endothelial vWF is exposed following injury. GPIb-IX-V complex, in fact, 
plays a leading role in the elimination of high-stress injury. However, GPIb-IX-V 
can be induced to bind vWF in plasma at high pathological shear stress (e.g., 
coronary artery is blocked by atherosclerotic plaque) [7].
2.2 GPVI
Platelet GPVI is a member of the T cell receptor family and immunoglobulin 
superfamily. It has two extracellular Ig domains: (a) mucin-like domain, a transmem-
brane domain, and (b) cytoplasmic tail (Table 1). These are expressed constitutively 
on platelets and are engaged during the exposure of collagen in the subendothelial 
matrix after disruption of the endothelium in vivo. Ligands for GPVI including colla-
gen, cross-linked collagen-related peptides, and the snake toxin, convulxin [85] may 
bind distinct sites of the Ig domains [23, 24]. GPVI can signal in response to collagen 
or other ligands by FcRγ receptor-dependent or receptor-independent pathways. 
The dependent pathway involves activation of Syk, and the independent pathway 
is regulated by calmodulin (via Ca2+ signaling pathways) or Fyn/Lyn kinase [7]. 
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The interaction of calmodulin with GPVI produces a soluble GPVI fragment [25].
Engagement of GPVI, the platelet integrins along with the collagen-binding recep-
tors α2β1 and αIIβ3 are found to be up regulated in the process of platelet aggregation 
[26]. The interaction between GPVI and collagen may be involved in the initiation of 
thrombus formation either at low or high shear rates. Further in the latter case, this 
thrombus formation possibly supports platelet aggregation, mediated by the GPIb-
IX-V complex and the vWF [26]. These signaling pathways result in secretion of 
agonists such as ADP and inside-out activation of platelet integrins, primarily αIIbβ3 
that binds fibrinogen or vWF and mediates platelet aggregation [26].
2.3 GPVI-FcRγ
Glycoprotein VI (GPVI), a transmembrane protein (63 kDa) consisting of two 
Ig-like domains in the extracellular region in platelets (Table 1). It connects to a 
highly glycosylated linker (a transmembrane domain) and a cytoplasmic tail. GPVI is 
expressed exclusively in platelets and megakaryocytes. In platelets, it expressed with 
around 3700 copies per platelet. The transmembrane adapter protein FcRγ is found 
to be associated with this. Surface expression of GPVI depends on FcRγ stabilization. 
This stabilization occurs through a salt bridge between the GPVI transmembrane 
domain residue Arg272 and FcRγ (Asp residues). The FcRγ is a covalent-linked 
homodimer containing one copy of an ITAM in each chain. It has two YxxL sequences 
separated by seven amino acids [27]. Phosphorylation of the ITAM motif by two 
Src kinases (Fyn and Lyn) associated with GPVI initiates platelet signaling, lead-
ing to potent platelet activation. SFKs for signal transmission are either associated 
with or in close proximity to their cytoplasmic tails. SFKs’ downstream effectors 
(adaptors, enzymes, and cytoskeletal proteins) collectively coordinate cytoskeletal 
remodeling, degranulation, membrane flipping, and integrin activation, and hence 
platelet activation. It has also been found that the SFKs act via the GPCRs. The Gq 
coupled with PAR-1 and PAR-4, and the Gi coupled with ADP receptor, P2Y12 which 
synergizes with the primary activation, signal to maximally activate platelets. GPVI 
is expressed in platelets as a mixture of monomers and dimers, with a stoichiometry 
of one GPVI to each FcRγ-chain covalent dimer. The dimeric GPVI forms a unique 
conformation with higher affinity for collagen to mediate activation at the physiologi-
cal concentrations of collagen, but not the monomeric GPVI due to its low affinity 
toward collagen [28]. F(αβ)2 fragments of antibodies to this structure induce platelet 
activation, while Fab fragments block activation by collagen, indicating a minimal 
signaling model in which activation is achieved through cross-linking of two GPVI 
dimmers [7]. Ligand-mediated clustering of different platelet receptors (GPIb-IX-V 
complex, GPVI-FcR γ, integrins α2β1 and αIIbβ3, hemi-ITAM-containing podoplanin 
receptor CLEC-2, ITAM-containing low-affinity immunoglobulin receptor FcγRIIA) 
trigger transmission of primary activation signals through the phosphorylation of 
downstream tyrosine residues in proteins. These receptors depend on the family of 
protein-tyrosine kinases, known as Src, but not on the intrinsic kinase activity.
2.4 Platelet integrins
Integrins play an important role in the cell metabolism of every cell, including 
platelets. The integrin ligands of platelets are partly extracellular matrix bound 
and insoluble, and partly soluble. Platelet adhesion and aggregation are mediated 
by the heterodimeric receptors, the β1 and β3 of integrins family. Integrins are 
expressed in a low-affinity state in the resting platelets, but to bind to their ligands 
efficiently in response to the cellular activation they (integrins) are found to be 
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shifted to a high-affinity state [29]. The integrin receptor for collagen on platelets, 
the α2β1, bears important roles at their disposal. A major downstream consequence 
of engagement of primary platelet adhesive receptors such as GPIb-IX-V and GPVI 
does rapidly activate platelet integrins.
Platelet integrins (Table 1 and Figure 1) are:
• αIIbβ3 (binds fibrinogen or vWF),
• αvβ3 (binds vitronectin),
• α2β1 (binds collagen),
• α5β1 (binds fibronectin), and
• α6β1 (binds laminin).
The Ca2+-dependent “inside-out” activation of αIIbβ3 to bind vWF is critically 
involved in stable thrombus formation at high shear stress. In the absence of αIIbβ3, 
activation of other integrins (e.g., α5β1-binding fibronectin) can at least partly 
compensate for this role [7]. Recent structural studies provide insight into the 
molecular mechanism of integrin activation [30]. Simultaneous with these confor-
mational changes, altered attachment of the cytoplasmic domain with cytoskeletal 
components (e.g., αIIbβ3 binding to talin) facilitates integrin-dependent cell adhe-
sion, signaling, and contraction.
2.4.1 αIIbβ3
The αIIbβ3 is the most abundant and dominant surface-expressed integrin in 
platelets (Figure 1). It may vary from 40,000 to 80,000 copies per platelet. Additional 
pool of this receptor can be recruited from internal membranes upon agonist-induced 
platelet activation. It is also the major functional integrin receptor on the platelet 
surface. The mature αIIb and β3 subunits are 148 and 95-kDa proteins, respectively. 
The αIIbβ3 binds with several RGD (Arg-Gly-Asp) motif containing ligands including 
fibrinogen, fibrin, vWF, vitronectin, fibronectin, and thrombospondin. During ligand 
recognition on platelet surface through RGD tract, fibrinogen (the major platelet 
αIIbβ3 ligand) promotes cell attachment by initiating αIIbβ3 clustering and recruit-
ment of intracellular proteins. The RGD motif subsequently acts as a molecular switch 
on the β3 subunit to induce a conformational change necessary for full cell spreading 
[31]. This integrin mediates platelet aggregation via the SFK signaling pathways 
through the binding of plasma fibrinogen. It serves as the principal receptor for platelet 
adhesion in vivo [7, 26] with the inside-out signaling. The shifting from a low- to a 
high-affinity state of integrin αIIbβ3 is being considered the “final common pathway” 
of platelet activation. It (shifting) is essential for platelet αIIbβ3 to interact with the 
fibrinogen during platelet adhesion. Needless to mention a well-known fact that 
fibrinogen itself is a ligand with two receptor interaction sites: (a) enabling interaction 
with separate platelets and (b) constituting the basis of platelet aggregation. At this 
stage of transmitting signals, the Src is found to be the most abundant SFK in human 
platelets and is essential for propagation of signals from the activated αIIbβ3 integrins.
2.4.2 αvβ3
The αvβ3 receptors express widely in endothelial cells, osteoblasts, smooth 
muscle cells, and leukocytes, and throughout the vascular bed. It is present in only 
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a few hundred copies per platelet. A distinguished difference lies between αvβ3 and 
αIIbβ3 in platelets. The αvβ3 can bind several RGD containing ligands, including 
osteopontin (a class of protein which involves diverse physiological functions) and 
adenovirus penton base (a major capsid protein of human adenovirus), but vitro-
nectin (a glycoprotein, binds to integrin αvβ3, and thus promotes cell adhesion and 
spreading) is a preferred ligand for αvβ3 [7]. High-affinity αvβ3 can be induced by 
agonists (adenosine diphosphate, ADP) and by direct integrin modulators (dithio-
threitol and MnCl2). This high affinity and activated αvβ3 on platelets can bind 
osteopontin in atherosclerotic plaques and in the wall of only injured arteries [27, 32].
2.4.3 α5β1
It has been found to be the crucial one to involve the resting platelet to bind with 
the fibronectin. The α5β1 is the principal platelet receptor which supports resting 
platelet to adhere with the matrix fibronectin through its RGD sequence in static 
conditions. However, this interaction is unable to promote calcium oscillation, tyro-
sine phosphorylation, and/or lamellipodia formation. The interaction of α5β1 with 
fibronectin is sensitive to shear stress (the tangential force of the flowing blood 
on the endothelial surface of the blood vessel), and it has been found that it loses 
its avidity quickly with the increase of the shear stress. Therefore, α5β1 may have 
the limited role to initiate the interaction of resting platelets with the fibronectin 
matrix. Especially during injuries in the larger blood vessels, where shear forces are 
low, it promotes the engagement of other subsequent integrins and also receptors to 
amplify platelet-induced responses [7].
2.4.4 α6β1
The α6β1, a principal laminin receptor of platelets, does not require any platelet 
activation in order to bind laminin (a fibrous protein present in the basal lamina of the 
epithelia, influencing cell differentiation and migration) to promote adhesion. Some 
cations (Mn2+, Co2+, and Mg2+) support adhesion, while few others (Ca2+, Zn2+, and 
Cu2+) do not help. Binding of platelets to laminin through α6β1 does not induce platelet 
aggregation but adherent of platelets to laminin triggers signaling pathways. These 
signaling pathways induce filopodia formation with PI3K and cdc42 activities in higher 
rate than in platelets which activates through αIIbβ3 involvement. Laminin has been 
known for many years to support adhesion of platelets through integrin α6β1, but it has 
the ability to activate GPVI. The interaction of laminin with GPVI depends on the initial 
interaction with integrin α6β1. This is just in contrast to the event of collagen interac-
tion which initiates platelet activation through GPVI. This difference between these 
interactions of these two matrix proteins may reflect the lower affinity (approximately 
10-fold) of laminin for GPVI or the presence of a subpopulation of constitutively active 
α6β1. The weak nature of the GPVI activation (by laminin) argues against a significant 
role in the prevention of major bleeds. It is suited ideally to facilitate vessel repair after 
minor damage without the risk of forming occlusive thrombi in the blood vessels [33].
Collagens are not only the most abundant proteins (20–40% of total proteins in 
the aorta) in the subendothelial extracellular matrix but also it is essential in platelet 
adherence and platelet plug formation to provide a mechanical strength to the blood 
vessel wall. There are nine types of collagen resides in the vasculature. Among 
those, only fibrillar collagens of types I, III, V, and VI and nonfibrillar collagens 
of types IV and VIII are thrombogenic. Although platelets have various types of 
receptors for collagen, the receptors (e.g., GPVI, α2β1, p65, p47, TIIICBP, GPIV, the 
integrin α2β1, and GPVI) are considered as its (platelets) major receptors for bind-
ing to collagens and activation of platelets [34].
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2.4.5 α2β1
The integrin α2β1 (or VLA2, CD49b/CD29, GPIa/IIa) is a collagen receptor 
composed of a α2 chain (150 kDa) and a β1 chain (130 kDa). This α2β1 has the 
expression profile ranging from 900 to 4000 copies/platelet and is expressed per 
platelet at about 2000 copies. The α2, inserted with 200-residue sequence, is the 
only platelet subunit with I domain. The crystal structure depicts that this domain 
comprises (a) seven helices surrounding a core of five parallel β-strands, (b) a short 
anti-parallel β-strand, and (c) a C-terminal helix [27]. The α2β1 integrin of this I 
domain binds with collagen and preferably Mg2+/Mn2+, in presence of the metal 
ion coordinating residues (D151, T221, and D254) in this site. Several recogni-
tion sequences (GFOGER, GLOGER, GASGER, GROGER, and GLOGEN) have 
been identified in collagens I and III. Their recognition profile in this recognition 
sequences have hierarchy and affinity differently [35]. This interaction is dependent 
on Mg2+ and the GER sequence. α2β1 recognizes these sequences in the resting 
state, but platelet activation by classical agonists via intracellular signal transduc-
tion pathways activates α2β1 via a structural rearrangement of the α2β1 domains 
[36], causing them to upregulate their affinity for their preferred ligand sequences, 
stereochemically positioned at regular positions on bundled collagen fibrils [35].
3. C-type lectin-like receptor
Another type of adhesion receptor is C-type lectin (CLEC), a type of carbo-
hydrate-binding protein domain. It requires calcium (that is why “C” comes) for 
binding. Proteins that contain C-type lectin domains have a diverse range of functions 
including cell-cell adhesion, immune response (to pathogens), and apoptosis. This 
kind of receptor is present on platelet to help in adhesion as another adhesion receptor.
3.1 CLEC-2
CLEC-2 is highly expressed in megakaryocytes and platelets, and at low 
level in mouse neutrophils. The CLEC-2 gene (on chromosome 12) codes for a 
type II membrane protein C-type lectin receptor family with an extracellular 
carbohydrate-like recognition domain (CRD-like). It has a cytoplasmic tail 
of 31 amino acids that contain a single conserved YxxL sequence (known as a 
hem-ITAM). CLEC-2 was discovered from the snake (the Malayan pit viper, 
Calloselasma rhodostoma) venom rhodocytin (Table 1), known as aggretin. 
Previously it (rhodocytin) was considered to be a platelet activator through 
the action of α2β1 and GPIbα. This concept was based on the ability of high 
concentrations of antibodies to block the activation. Now it has been found that 
rhodocytin does not bind to the recombinant α2β1, as it has the ability to activate 
platelets even in the deficiency of integrin α2β1, GPIbα, and GPVI. Thus, it is a 
proven fact now that this rhodocytin appears to activate platelets through a novel 
receptor, CLEC-2. The CLEC-2 antibody establishes CLEC-2 as a novel platelet 
activation receptor as it has the ability to induce the potent activation to human 
platelets [37]. Experimenting with ligand and anti-CLEC-2 antibody, it has been 
found that Syk mediates phosphorylation of CLEC-2 with Src family kinases 
plays a critical role in further downstream signaling [7]. The rhodocytin-induced 
platelet aggregation also previously known to depend on secondary mediators 
(e.g., thromboxane A2, TXA2, and ADP) acted as agonists for GPCRs on platelets. 
Recently, it has been found that CLEC-2-induced Syk and PLCγ2 phosphorylation 
potentiates by the TxA2 by playing a critical role in the most proximal event of 
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CLEC-2 signaling (i.e., CLEC-2 receptor tyrosine phosphorylation). In addition, 
it may be mentioned that the ADP receptors and protease-activated receptors can 
also potentiate CLEC-2 signaling during the process of thrombosis formation. The 
PLCβ-PKCα pathway possibly is regulating the activation of SFKs (mentioned 
earlier), which are crucial for initiation of CLEC-2 signaling by the Gq-coupled 
receptors, not other G-proteins.
Amplification of platelet activation by TXA2 synthesis and binding to the TXA2/
prostaglandin H2 (TP) receptor are the process of the aspirin-sensitive platelet acti-
vation (Figure 1). On the other hand, prostacyclin (PGI2) and PGD2 are known to 
inhibit platelet aggregation, whereas PGE2 potentiates or inhibits platelet response 
in a dose-dependent manner [7]. In this context, it may be mentioned that bioactive 
lipid mediators, prostanoids, formed from arachidonic acid by the cyclooxygenase 
enzyme is known to liberate from the cell membrane. They are involved in numer-
ous physiological activities, including platelet aggregation, local inflammatory 
response, leucocyte-endothelial cell adhesion, and vasorelaxation as well as vaso-
constriction. So, the thromboxane as well as PGs are other types of platelet adhesion 
receptors to discuss with.
4. Thromboxane receptor
TXA2 is produced from its precursor arachidonic acid through the cyclooxygen-
ase pathway [38]. The TP receptor or TXA2/PGH2 receptor (57 kDa) is a membrane-
bound seven transmembrane spanning G protein-coupled (including Gq and 
G12/13) receptor and widely present in the cardiovascular system (Table 1). Human 
TP receptors (TPα and TPβ) are encoded by the same gene, but different from 
each other as they produce from alternative splicing and have different C-terminal 
intracytoplasmic regions. Both TPα and TPβ mRNAs are found in platelets, but in 
endothelial cells, only TPβ has been found to be expressed. TP receptors are also 
expressed in other cell types related to atherothrombosis (smooth muscle cells, 
macrophages, and monocytes) [39, 40].
5. Prostaglandin (PG) receptors
The PG receptors, especially PGE2 and PGI2, bear a pivotal responsibility in 
platelet aggregation phenomena to maintain hemostasis, as mentioned earlier.
5.1 Prostaglandin E2 receptors (PGE2)
The biosynthesis of PGE2 is enhanced by inflammatory mediators in vas-
cular smooth muscle cells and macrophages (Table 1). PGE2 shows a biphasic, 
concentration-dependent effect on platelet aggregation as (a) high concentrations 
of PG inhibit platelet aggregation, whereas (b) lower concentrations enhance it. 
PGE2 activates four types (PGE2 type 1 or EP1, PGE2 type 2 or EP2, PGE2 type 3 
or EP3, and PGE2 type 4 or EP4) of its G protein-coupled receptors. Each of these 
receptors has a distinct pharmacological signature and intracellular signal transduc-
tion. Stimulation of EP3 receptors results in elevation of free intracellular calcium 
levels, whereas stimulation of EP2 and EP4 receptors usually decreases intracellular 
calcium levels due to increase in intracellular cAMP levels through the activation of 
Gas (growth arrest-specific) protein [41]. It may further be mentioned that except 
EP2 receptor, the mRNA for EP1, EP3, and EP4 receptors is present in human 
platelets [41].
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The activation of the EP3 receptor by leading to inhibition of the increase in 
cAMP increases the mobilization of calcium and elevates P-selectin expression in 
platelets ascribing the proaggregatory effect of PGE2. Lacking of this receptor has 
been found to show an increased bleeding tendency and a decreased susceptibil-
ity to thromboembolism [42], but PGE2 produced by atherosclerotic plaques can 
further facilitate arterial thrombosis via EP3 [43]. Interestingly, no defects in 
the EP3 receptor gene have been found in humans [7]. The platelet aggregation, 
calcium mobilization, and upregulation of P-selectin are found to be inhibited 
by the selective EP4 agonist, ONO AE1-329. Additionally, the EP4 antagonists, 
GW627368x and ONO AE3-208, have been found to repeal the inhibitory effect 
of ONO AE1-329 on platelet aggregation [44]. Thus, the EP4 receptors might 
play an important role mediating the inhibitory effect of PGE2 in the control 
of hemostasis by balancing out the proaggregatory effect of EP3 receptors. EP4 
agonists might constitute a novel class of antithrombotic agents and also might be 
clinically useful in those cases where aspirin or ADP antagonists are not war-
ranted or are insufficient, as the EP4 activation enhances the inhibitory effect of 
aspirin [44].
5.2 Prostaglandin I2 (PGI2) or prostacyclin receptor
Prostaglandin I2 (PGI2) or prostacyclin is a derivative of arachidonic acid, 
released by vascular endothelial cells (Table 1). It is an effective (a) vasodilator, 
(b) platelet aggregation inhibitor, and (c) moderator of vascular smooth muscle 
cell proliferation-migration-differentiation (anti-atherosclerotic). It acts through 
a specific membrane-bound receptor, the prostacyclin receptor (IP receptor). The 
IP receptor belongs to the prostanoid family of GPCR. The receptor (37–41 kDa, 
depending upon different states of glycosylation) are class A rhodopsin-like GPCR. 
The glycosylation of the extracellular domain is necessary for (a) ligand bind-
ing, (b) receptor activation, and (c) membrane localization. A number of serine 
residues (S328 and S374) are thought to be phosphorylated by GPCR kinases or 
second-messenger-activated kinases (PKC and PKA) in the cytoplasmic domain. 
It might play a potential role in either agonist-induced phosphorylation or kinase-
mediated receptor desensitization [45]. Cyclopentane ring and side chains are the 
two structural features of prostaglandins. Among these, the side chains are found 
to be recognized by their receptor to stabilize ligand binding, and the binding 
pocket of the receptor can accommodate the cyclopentane rings (PGI2, PGE1, and 
PGE2). The IP is the most common to be associated with the Gas subunit of the 
heterotrimeric G-protein. Upon receptor activation, it has been found to catalyze 
the formation of the second messenger, cAMP by stimulating the membrane-bound 
adenylyl cyclase [7].
The discussion with GP, TX, and PG lead us to discuss with thrombin receptor as 
stimulation of thrombin activates the thrombin receptors in vivo.
6. Thrombin receptors
As explained earlier, platelet activation by thrombin partially depends on GPIb-
IX-V, but is primarily assured by two protease-activated receptors (PAR), i.e., PAR-1 
and PAR-4. Binding of thrombin (immobilized, proteolytically inactive) to GPIb 
induces platelet adhesion as well as spreading and secretion [19], being an enhancer 
(GPIb) of the thrombin response (see Section 2.1). PAR-1 and PAR-4 (Table 1) are 
activated by a unique irreversible proteolytic cleavage (within the first extracel-
lular loop exposing an N-terminus) by serving as a tethered ligand to GPIb. Short 
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synthetic peptide mimetic of the N-terminus sequences, corresponding to the new 
N-terminus, reproducing most of the action of thrombin on platelets upon cleavage 
by thrombin (SFLLR for PAR-1 and GYPGQV for PAR-4) can activate these recep-
tors directly. This dual-receptor (PAR-1 and PAR-4) signaling for thrombin implies 
that PAR-1 is the primary mediator that activates platelets at low concentration, 
whereas PAR-4 as a back-up receptor is found to be activated at higher thrombin 
concentrations. For sustained optimal platelet responses to thrombin, the qualita-
tive differences in the dynamics of PAR-1 and PAR-4 activation might be relevant. 
The signaling for PAR-4 at high thrombin concentrations acts very slowly, as the 
PAR-4-mediated Ca2+ mobilization is found to be slower and more prolonged than 
that of PAR-1, and also, this activity terminates more slowly. Interestingly, there is 
no such report with congenital deficiencies of PAR receptors in any individuals. The 
pharmacological invention of PAR-1 inhibitors will be very helpful to prevent the 
platelet-dependent thrombosis in the first stage [46].
On the surface of platelet membrane a type of kinase receptors are present which 
are specific to its ligand and associated with integrin receptors to act with, known as 
ephrin kinase receptor.
7. Ephrin (Eph) kinase receptors
Eph kinases are receptors expressed on the surface of cells. It activates in 
response to binding with Eph receptor-interacting proteins, ephrins. Eph kinases are 
known to be a member of receptor tyrosine kinases subfamily with an extracellular 
ligand binding domain and an intracellular tyrosine kinase domain (Table 1). The 
EphB is distinguished from the EphA subfamily by an insertion within the extracel-
lular domain that helps to define the ligand preferences for the receptor. EphrinA to 
EphA interaction (Table 1) occurs typically with higher affinity than ephrinB (to 
EphB) interactions. This may be due to the fact that EphAs bind via a “lock-and-
key” mechanism with little conformational change with less energy, in contrast to 
EphBs which utilizes an “induced fit” mechanism with a greater amount of energy 
to alter the conformation of EphBs for binding to ephrinBs [47]. The Eph kinase and 
ephrin interactions on adjacent cells play a pivotal role in neuronal patterning and 
vasculogenesis. Eph subtypes of EphA4, EphB1, and also ephrinB1 are found to be 
expressed by the human platelets. In both resting and activated platelets, the EphA4 
is constitutively associated with αIIbβ3. Fine tuning between the Eph and ephrin is 
very much essential as clustering of either EphA4 or ephrinB1 causes platelet adhe-
sion to immobilize fibrinogen, whereas by blocking this (Eph/ephrin) interaction, 
the clot retraction can be hampered. This may cause platelet aggregation inhibition 
at low agonist concentrations and may form smaller thrombi on collagen-coated 
surfaces during normal conditions of arterial flow. This can develop premature 
disaggregation. It acts partially due to the ability of ephrin B1 to activate Rap1 (a Ras 
family member)-mediated signaling which supports platelets activation, especially 
the integrin in platelets [48].
There are also purinergic (P) receptors, present on the platelet membrane, 
which are basically ADP or ATP dependents.
8. Purinergic receptors
These purinergic receptors reside in coupled form, that is why it represents 
as P2. These P2 (purinergic coupled) receptors are of mainly three types—P2Y1, 
P2Y12, and P2X1 (Table 1).
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8.1 P2Y1
The P2Y1 receptors (42-kDa, contain 373 amino acid residues) are widely 
distributed in many tissues (heart, blood vessels, smooth muscle cells, neural tissue, 
testis, prostate, and ovary) including platelets. About 150 P2Y1 receptor-binding 
sites are expressed per platelet, and it is also abundantly represented in membranes 
of α-granules and elements of the open canalicular system. The P2Y1 receptor is 
absolutely required for ADP-induced platelet aggregation. ADP is a more potent 
agonist than ATP, and its 2-methylthio derivatives are more potent than the parent 
compounds. ATP is a partial agonist for the P2Y1 receptor, and at the low levels 
of receptor expression, it acts as an antagonist. Overall, P2Y1 accounts for about 
20–30% of the total ADP-binding sites on the platelet surface [49]. At the P2Y1 
locus, a common genetic variant (dimorphism, 1622AG) exist which is associated 
with platelet reactivity to ADP. However, this can partly explain the interindividual 
variation in platelet’s response to ADP and may have clinical implications in relation 
to the thrombus formation [7].
8.2 P2Y12
The purinergic P2Y12, the Gi-coupled platelet receptor, exists in platelets, 
smooth muscle cells, endothelial cells, and glial cells. This surface protein is 
expressed from the chromosome 3q21–25 containing 342 amino acid residues 
which includes extracellular Cys residues at four different locations (17, 97, 175, 
and 270, respectively). The Cys 97 and Cys 175 are found to be linked by a disulfide 
bridge, and this link is important for receptor expression in platelets. P2Y12 recep-
tor exists predominantly on the platelet surface among the purinergic receptors as 
homo-oligomers placed in lipid rafts. The active metabolite of clopidogrel (which 
covalently inhibits P2Y12) application as treatment disrupts the homo-oligomers 
into nonfunctional dimers and monomers which are sequestered outside the lipid 
rafts [7]. ADP and its analogs (e.g., 2-methylthio-ADP and N-methanocarba-2-
methylthio-ADP) stimulate the P2Y12 receptor, while ATP and its triphosphate 
analogs act as antagonists to it [7]. P2Y12 plays a central role for ADP in platelet 
function. The congenital P2Y12 defective patients display a mild to moderate bleed-
ing diathesis with the conditions of mucocutaneous bleedings and postsurgical and 
posttraumatic excessive blood loss. Any defects of P2Y12 can also be thought of 
even when high concentrations (10 mM) of ADP is unable to induce full, irrevers-
ible aggregation of platelets [49].
8.3 P2X1
P2X1 is a widely distributed ligand-gated ion channel, highly expressed in 
human megakaryocytes and platelets. It is well known that ATP is the physiologi-
cal agonist and ADP is an antagonist. Platelet dense granules release ATP upon its 
activation with an ion channel (cationic and/or anionic) present on platelets, i.e., 
P2X1. During platelet preparation under in vitro condition, a rapid desensitization 
of the P2X1 receptor occurs which made this receptor unnoticed. The P2X1 gene 
lies on the chromosome 17p13.2. It encodes 399 amino acids which are organized 
into two transmembrane domains (TM1 and TM2). These are separated by a large 
extracellular domain containing 10 cysteine residues. Three molecules of ATP 
bind to the extracellular domain of P2X1 and trigger conformational changes. This 
results in the opening of a cationic pore for monovalent and divalent cations (e.g., 
Ca2+, Na+, and K+) allowing rapid changes in the membrane permeability. P2X1 
receptor activation triggers transient shape change of a platelet from a discoid to 
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spherical shape; furthermore, in presence of low concentrations of other platelet 
agonists, it (activation of P2X1) amplifies platelet responses. The P2X1 receptor 
contributes equally to low and high levels of thromboxane A2 receptor activation. 
More significantly, P2X1 receptor activation has been shown to be essential for 
enhanced platelet adhesion and thrombus formation under high shear rates [50]. 
P2X1 is distinguished as a potential new drug target for antithrombotic therapy, 
especially for the mild long-term risk management. As inhibition of P2X1 causes 
mild effects on different platelet function, it (P2X1) seems to be a so-called “safe” 
target clinically [51].
As mentioned earlier (see Section 5.1), Gas receptors also have some important 
role in the stabilization of platelet aggregation to maintain internal hemostasis.
9. TAM receptor and Gas6
Gas6 has its interactions with Tyro 3, Axl, and Mer (TAM) tyrosine kinase 
receptors (Figure 1). It is a vitamin K-dependent protein implicated in cell 
growth, adhesion, and migration, through its TAM receptor. These three related 
protein receptors (TAM) were cloned (in 1991) as orphan receptors and have 
been found to be widely expressed in the vertebrate nervous system [7]. They 
(TAM receptors) have two N-terminal immunoglobulin domains, followed by 
two fibronectin-III-like domains to mediate binding to the ligand. These domains 
are found to be attached to an intracellular tyrosine kinase domain, via a single-
pass α-helical transmembrane domain. The functional receptors form both the 
hetero- and homo-dimers, which is common with other receptor tyrosine kinases 
(Table 1 and Figure 1).
It (Gas6) is found in plasma and platelet granules, but in human, it is present 
predominantly in plasma. It is secreted upon platelet activation, as mentioned ear-
lier. Deficiency in Gas6 or one of its receptors (TAM) in mice has shown abnormal 
platelet responses to agonists and prevents thrombosis, suggesting a major role of 
this Gas6-TAM receptor-coupled axis in thrombus formation as well as in vascular 
wall homeostasis. The role of Gas6 in human platelet function has been clarified 
with the fact that the Gas-6 reinforced αIIbβ3 integrin with the outside-in signal-
ing by the activation of PI3K and Akt and therefore clot retraction by promoting 
the β3 phosphorylation [52]. These effects constitute in fact an enhancement and 
perpetuation of the thrombus-stabilizing role of ADP. The inhibition of Gas6 
signaling has been proposed as an attractive target for novel antithrombotic 
drugs [53].
Many receptors are known of transmembrane family. There is also a unique tet-
raspan transmembrane receptors on the platelet membrane, known as tetraspanin 
receptors.
10. Tetraspanin receptors
Tetraspans, mean four transmembrane domains, called as tetraspanins belong 
to the transmembrane 4 superfamily (TM4SF) receptors. Usually, tetraspanins are 
found to act as scaffolding proteins. It has intracellular (N- and C-) termini and two 
extracellular domains (EC1 and EC2), arranged in a way of one short and one long 
with typically 100 amino acid residue long loop. Its EC2 domain with four or more 
cysteine residues are its main feature, among which two are in a highly conserved 
“CCG” pattern. It can anchor multiple proteins to one area of platelet cell mem-
brane [7].
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10.1 CD151
The CD151, a tetraspanin superfamily member, previously termed as PETA-3/
SFA-1 has been found to express broadly in hematopoietic, vascular, and immune 
compartments, and especially abundant in cardiac muscle, endothelia, epithelia, 
megakaryocytes, smooth muscle, and the platelets. It is found to functionally link 
with the integrin trafficking, cell migration, cancer metastasis, neurite outgrowth, 
hemidesmosome formation, vascular morphogenesis, wound healing, immune 
responsiveness, and hemostasis. CD151 has been found to appear to regulate 
fibrinogen-binding proteins (e.g., integrin αIIbβ3) (Table 1). In addition, the 
absence of CD151 in vivo leads to smaller, unstable thrombi formation [54].
10.2 TSSC6
The TSSC6 or tumor-suppressing subchromosomal transferable fragment 
cDNA 6 also called as pan-hematopoietic expression (Phemx). It is a member of 
tetraspanin superfamily. Its C-terminal cytoplasmic domain is relatively large (33 
amino acids in mouse and 99 amino acids in human) than the other members of 
the tetraspanin superfamily [55]. TSSC6 may modulate hematopoietic cell function 
specifically when expressed in hematopoietic organs and tissues. It is expressed on 
the surface of murine platelets and is upregulated by thrombin stimulation. The 
secondary stability of arterial thrombi formation (by regulating integrin αIIbβ3 
outside-in signaling events) has been found to affect upon vascular injury dur-
ing the lack of platelet TSSC6 receptors in vivo (Figure 1) [55]. The proliferation 
of T lymphocytes has also been observed in the TSSC6-deficient mice, due to the 
increase in interleukin 2 production following T-cell receptor stimulation, providing 
a clue to the negative regulation of peripheral T-lymphocyte proliferation by TSSC6.
10.3 CD36
CD36 (80–90 kDa) is known to be a scavenger receptor. This CD36 along with 
other receptors and their corresponding subunits (GPIIIb, GPIV, GP88, FAT, 
SCARB3, or PASIV) are expressed on the surface of the platelets and other cells 
(e.g., monocytes, endothelial cells, smooth muscle cells, and cardiomyocytes). 
Approximately 10,000–25,000 molecules are present in a single platelet. Its gene is 
located on the chromosome 7, in case of human.
It consists of a single peptide chain (consisting of 474 amino acids). Its two 
transmembrane domains (one near the N-terminus and the other near the 
C-terminus) are configured like a “hairpin-like” structure. The domains of CD36 
are separated by a large, glycosylated extracellular loop. It (CD36) was initially 
described as a collagen receptor of types I and III on platelets, but later, it has been 
found that it is not a primary collagen receptor as its binding to the nonfibril-
lar type V collagen has been documented [56]. The interaction of CD36 with its 
various ligands (e.g., thrombospondin 1 or TSP1, long chain fatty acids, oxidized 
phospholipids or oxPL, and oxidized low-density lipoprotein or oxLDL) is found to 
modulate the platelet activation (Table 1). TSP-1 is found to promote platelet aggre-
gation through the modulation of an inhibitory signaling pathway. TSP-1 binding 
to its receptor CD36 prevents cAMP/protein kinase A (PKA) signaling. Indeed, 
TSP1 triggers CD36-dependent signals that reduce platelet sensitivity to PGE1. 
It (CD36-dependent signaling) diminished its (PGE1) ability to inhibit platelet 
aggregation and arrest under conditions of flow [57]. Other CD36 ligand, oxLDL, 
formed during hyperlipidemia and atherosclerosis can also activate platelets in 
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a CD36-dependent manner, as stated in TSP1. The level of platelet CD36 surface 
expression is highly variable among individuals within general population with 
inheritance of specific genotypic polymorphisms at the CD36 locus (Figure 1) [58].
10.4 TLT-1
Another member of this tetraspan superfamily is the triggering receptors 
expressed in myeloid cells or TREMs, which are found to be involved in the acti-
vation of various cell types of the innate immune system. It includes platelets, 
monocytes, macrophages, microglia, and neutrophils. The family is characterized 
by a single V-set immunoglobulin (Ig) domain, a short cytoplasmic tail, and a 
charged residue in the transmembrane domain. TREM-like transcript-1 (TLT-1 or 
TREML-1) is a type I single Ig domain orphan receptor. It is specific to platelet and 
megakaryocyte alpha-granules. It only relocates to the platelet surface upon platelet 
stimulation. Its longer cytoplasmic tail carries a canonical ITIM (immunoreceptor 
tyrosine-based inhibition motif) which is capable of becoming phosphorylated 
and of binding to the Src homology-containing protein tyrosine phosphatase-1 
(SHP-1). It (ITIM) can identify TLT-1 as the only putative inhibitory member of the 
TREM cluster. During storage, the ability of anti-TLT-1 scFv (single chain variable 
fragment) to block aggregation of washed platelets suggested that TLT-1 facilitates 
thrombosis by interacting with ligand(s) in activated platelets. TLT-1 acts in col-
laboration with αIIbβ3 to facilitate fibrinogen/platelet interactions and/or higher 
order platelet aggregation following the same signaling mechanism (Figure 1 and 
Table 1) [59, 60].
10.5 PEAR1
The PEAR1 or platelet endothelial aggregation receptor-1 (150 kDa) is known 
as multiple epithelium growth factor 12 (MEGF12) or Jedi-1. Interestingly, “Jedi” 
is not a scientific name here, which is being used by the scientists. It is a myth to 
describe the power and devotion of a knight, known as Jedi knights who respect all 
life by defending and protecting those who cannot do encounter for themselves, 
and in any altercations, they remain ready to encounter and fight only in self-
defense and for the defense of those they protect. Based on this myth’s symbolic 
importance and strength of PEAR-1 receptor in the maintenance of homeostasis, it 
was named so.
It is a transmembrane protein of the MEGF-like domain protein family. It is 
mainly expressed in platelets, endothelial cells, and also in satellite glial cell precur-
sors. During development, it is necessary for the clearance of apoptotic neurons via 
phagocytosis in the embryonic dorsal root ganglia (DRG). PEAR1 is composed of (a) 
an extracellular Emilin domain (EMI domain), (b) 15 extracellular EGF-like repeats, 
and (c) multiple cytoplasmic tyrosines and pralines, (d) intracellular domain struc-
ture, containing 5 proline-rich domains and an NPXY motive (serving as a phos-
photyrosine-binding site and an internalization signal). During platelet aggregation, 
PEAR1 is phosphorylated at Tyr-925 and Ser-953/1029 in an αIIbβ3-dependent man-
ner of signaling mechanism, as described previously. The PEAR1 has been hypoth-
esized as a platelet-platelet contact receptor, due to its (PEAR1) αIIbβ3-independent 
phosphorylation [61]. The high-affinity immunoglobulin E receptor subunit α 
(FcεR1α) has been found as PEAR1 ligand (Table 1). PEAR1 promoter-region variant 
(rs2768759) was associated with increased aggregation in PRP, most strongly in 
response to epinephrine, in both pre- and post-aspirin treatment conditions [62]. 
Increased expression of PEAR1 might be an important cause of hyperactivity [62] 
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and genetic variation within PEAR1, particularly rs41299597, seems to lead to an 
increased membrane expression of PEAR1 in activated platelets and elevated respon-
siveness to GPVI ligands [63]. A genome-wide meta-analysis linked the minor allele 
of the PEAR1 SNP (rs12566888) to a drop in aggregation response toward ADP and 
epinephrine in the European and African-ancestry sample [64].
Cell-cell adhesion is very important in the process of thrombus formation and 
obviously to extend the formation into proper stability until the proper clot forms. In 
this process, a specific adhesion molecule and its specific ligand have been found to 
play an important and interesting role to maintain hemostasis. P-selectin is a member 
of the selectin family of adhesion molecules. P-selectin glycoprotein ligand-1 (PSGL-
1) on the plasma membranes of neutrophils or monocytes, which are key effector 
cells of the innate immune system, binds to P-selectin translocated to the surfaces 
(Figure 1 and Table 1) of the inflamed endothelial cells or activated platelets [65].
11. P-selectin
Selectins are a family of cell adhesion molecules (CAMs). It is also known as 
clusters of differentiation 62 or CD62. It is present in endothelium (as E-selectin, 
58.6 kDa), leukocyte (as L-selectin, 30 kDa), and platelets (as P-selectin). P-selectin 
has a molecular weight of 86 kDa based on the prediction from its cDNA, but 
from reducing SDS-PAGE, it is about 140 kDa. The primary ligand for P-selectin is 
P-selectin glycoprotein ligand-1, known as PSGL-1 which is found constitutively on 
all leukocytes (Table 1). The transient interactions between P-selectin of activated 
platelets and PSGL-1 of leukocytes allow them to roll along the venular endothelium. 
During this activation of the coagulation cascade, the formation of a fibrin network 
is found to be a critical event in thrombus stability (Figure 1). A laser injury-induced 
thrombosis is found to express a low level of tissue factor (TF) in mice. It has also 
been shown that this fibrin formation depends on the monocyte-derived TF, carried 
by microvesicules, with minimal contribution of vessel wall TF. These microve-
sicules are captured onto the thrombus through the interaction between P-selectin 
and PSGL-1 (as mentioned before) present on microvesicules, hence delivering TF 
to the growing thrombus. Based on this observation, studies with mice, deficient 
in either PSGL-1 or P-selectin display thrombi with little TF and reduced thrombin 
generation, resulting in hampered thrombus size [7, 65]. Elevated plasma P-selectin 
(normal value 100 ng/ml in man) is a major predictive factor of cardiovascular 
events related to platelet turnover and its activation as well as function. So, the 
increase in P-selectin expression is expected to develop the artery diseases of periph-
eral tissues, stroke, and even the acute myocardial infarctions [7].
Being a dynamic process, a state of surface is preferable in the arterial thrombus 
formation to limit thrombus growth passively. In this context, it is not unreasonable 
to mention here that the essential roles of nitric oxide (NO) and PGI2 in the negative 
regulation of platelets to prevent uncontrolled thrombosis have been well established 
[7]. However, the inhibitory role of various receptors with and without immunore-
ceptor tyrosine-based inhibition motif (ITIM) domain for active thrombus forma-
tion is well recognized [7, 65]. It is very important to limit the thrombus formation 
within the blood vessels. These receptors are now in focus of our discussion.
12. ITIM-containing receptors
Immunoreceptor tyrosine-based inhibition motifs or ITIMs are defined by a 
consensus sequence of (L/I/V/S)-X-Y-X-X-(L/V); ITIM-containing receptors are 
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found in pairs, separated from each other by 15–30 amino acid residues, were 
originally identified by their ability to inhibit signaling by its activation counterpart 
(immunoreceptor tyrosine-based activation motif or ITAM) receptors. The ITAM 
and ITAM-like receptors, GPVI and CLEC-2 in the presence of thrombin (a GPCR 
agonist), cause mild inhibition of platelet activation by the platelet endothelial cell 
adhesion molecule or PECAM-1. The action of this inhibition by the thrombin, 
GPVI, CLEC-2, and PECAM-1 is similar to that of G6b-B in which it (G6b-B) can 
inhibit the SFK (Src and Syk) signaling to prevent unwanted platelet activation. 
This signaling mechanism also shows the inhibition of platelet activation by the 
GPVI-specific agonist (collagen-related peptide) and ADP (an agonist of GPCR) 
(Table 1 and Figure 1).
12.1 PECAM-1
PECAM-1 (or CD31, molecular weight 130 kDa), the adhesion molecule, bears 
a pivotal role in the negative regulation of platelet aggregation by inhibiting the 
platelet activation. PECAM-1 is expressed on the cell surface of hematopoietic 
and immune cells, which include platelets, neutrophils, monocytes, megakaryo-
cytes, natural killer cells, some T cells, and on endothelial cells, particularly at the 
borders of the adjacent cells. PECAM-1 is a member of the Ig superfamily (like 
GPVI receptor), consists of (a) six extracellular Ig domains, (b) transmembrane 
domain, and (c) cytoplasmic tail. The cytoplasmic domain contains an ITIM, 
which becomes phosphorylated upon stimulation by homophilic interactions 
and/or clustering. PECAM-1 is found to ease the recruitment of tyrosine, serine/
threonine, sometimes possibly the lipid phosphatases, and consequent kinase-
dependent signaling inhibition to inhibit the platelet activation by attenuating 
the thrombus formation and thrombin-mediated platelet activation (by means 
of negative regulation) involving GPVI and GPIb (Table 1) [66]. PECAM-1 is an 
efficient signaling molecule in platelet and is capable of exhibiting both outside-
in and inside-out signaling. PECAM-1 is also implicated in numerous other 
biological functions including apoptosis, platelet aggregation, thrombosis, and 
angiogenesis.
12.2 G6b-B
Among the novel plasma membrane proteins (identified via proteomics study), 
the immunoglobulin superfamily member G6b is one of them. It consists of 241 
amino acids (26 kDa). It is found to undergo extensive alternate splicing. In stimu-
lated platelets, G6b-B undergoes tyrosine phosphorylation in association with the Src 
homology-2 (SH2) domain-containing phosphatase (SHP-1). It suggests its impor-
tance to play a novel role in limiting platelet activation. Only the G6b-B is found to 
have both (a) a transmembrane region and (b) two ITIM. This ITIM supports bind-
ing to the two SHPs, i.e., SHP1 and SHP2. Heparan sulfate has recently been found 
as a ligand for G6b-B receptors (Table 1). The second ITIM, with a slightly different 
sequence (TXYXXV), is located around 20 amino acids downstream of the first 
ITIM of G6b-B [67]. In addition, G6b-B is encoded by a gene that is variously called 
G6b, C6orf25, or MPIG6B. It is a platelet and megakaryocyte-specific receptor.
12.3 VPAC1
VPAC1 is the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-
activating peptide (PACAP) receptor 1. The PACAP is a neuropeptide of the VIP, 
a member of secretin/glucagon superfamily. The PACAP receptor (vasoactive 
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intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1) or 
VPAC1 in platelets is coupled to adenylyl cyclase activation. The VPAC1 and VPAC2 
are found to couple with the G-protein (Gs) resulting in the stimulation of cell 
adenylyl cyclase. The VPAC1, together with the VPAC2 receptor subtype, mediates 
a large array of VIP or pituitary adenylate cyclase activating peptide actions on dif-
ferent physiological functions including exocrine secretions, release of hormones, 
relaxation of muscles, metabolism, growth control of fetuses, and embryonic brain 
development. Patients with severe mental retardation have found to have a bleed-
ing tendency with mild thrombocytopenia. Increased basal cAMP level in platelets 
is providing a basis for the reduced platelet aggregation. Megakaryocyte-specific 
transgenic overexpression of PACAP consequently increased the PACAP release 
from platelets to reduce the platelet activation and thereby prolongation of the 
bleeding time. In the management of arterial thrombosis and arterial bleeding, the 
therapeutic potential of PACAP is now considering clinical practices as inhibitor of 
thrombus formation [68].
13. Toll-like receptors (TLRs)
These are transmembrane proteins consisting of a lipoprotein receptor-related 
protein (LRP) extracellular domain, a transmembrane region, and a Toll-IL-1R 
domain, present on the surface of platelets. These exist in smaller amounts than 
GPIb-IX-V complex. Human platelet TLRs are similar to Toll receptor in Drosophila 
with four types (TLR-1, TLR-2, TLR-4, and TLR-6). However, platelets and 
megakaryocytes express mRNA and/or protein for different TLRs (e.g., TLR-1, 
TLR-2, TLR-3, TLR-4, TLR-6, TLR-7, TLR-8, and TLR-9) that detect and bind viral 
components and nucleic acids at the cell surface [69]. These TLRs (Table 1) play an 
important role in innate immunity by their ability to identify the products of bacte-
ria, viruses, protozoa, and fungi, and important for their clearance (Table 2). After 
identification of these products, TLRs activate intracellular signaling pathways to 
Receptors Viruses
αvβ3 Hantaviruses, coxsackieviruses A9 and A16, human 
adenovirus type 2, echovirus 9, and human parechovirus
αIIbβ3 Human parechovirus
α 2β1 Echovirus 1 and rotavirus
DC-SIGN Lentivirus, HIV, and Ebola virus
Axl Lassa fever virus (LASV)
Tyro3; CCR-3 and -4; CXCR-1, -2, and -4; 
CLEC-2; DC-SIGN
HIV
GP-VI HCV
CR2 EBV
α2β1 Rotavirus
α2bβ3 (GPIIbβ3a) Adenovirus
CLEC-2: C-type lectin-like type II transmembrane receptor; CR: complement receptor; CCR: C-C chemokine 
receptor; CXCR: C-X-C chemokine receptor; DC-SIGN: dendritic cell-specific intercellular adhesion molecule-3-
grabbing; non-integrin; GP-VI: glycoprotein VI. Other details of platelet receptors are same as presented in Table 1. 
(This table is adopted from Seyoum et al. [69].)
Table 2. 
Different classes of platelet receptors for viruses.
21
Molecular Aspects of Pathophysiology of Platelet Receptors
DOI: http://dx.doi.org/10.5772/intechopen.92856
induce an inflammatory response [70]. TLR-4 promotes platelet-neutrophil interac-
tion and also causes activation of the neutrophils [71]. However, the involvement of 
FcγRIIA and serotonin may not be ignored [72].
14. Serotonin receptors
Serotonin (5-hydroxytryptamin) receptor of 2A type or 5-HT2A and 5-HT3A 
has also been found on platelet membrane [73, 74]. Platelet activation has been 
found to release stored serotonin from dense granules by amplifying release 
reaction and thereby promoting platelet aggregation. However, serotonin itself 
does not cause platelet aggregation but enhances platelet aggregation, induced 
by its other agonists (e.g., ADP and thrombin) [75]. It has been depicted that 
the interaction of 5-HT2A with serotonin initiates calcium signaling. The 5-HT3 
receptor has been found to increase immunoreactivity with the platelet activation 
(with ADP and thrombin receptor activating peptide, TRAP). Serotonin is also 
known to cause vasoconstriction of the blood vessels with damaged endothelium 
and promotes thrombus formation. It has the ability to attach to a large number 
of substrates including fibrinogen, vWF, thrombospondin, and fibronectin 
[76]. The release of serotonin precedes the neutrophil contribution to shock, 
consistent with the reported role of serotonin in neutrophil activation (Table 1 
and Figure 1). The vasodilation was also present in the absence of neutrophils, 
suggesting that the platelets orchestrate neutrophil activation and endothelial 
cell functions through serotonin and this event can occur independently critically 
with the FcγRIIA and serotonin [72].
15. Leucine-rich repeat receptors (LRRs)
The LRR is a protein structural motif with a repetition of 20–30 amino acids 
which are rich in leucine, a hydrophobic amino acid. It is involved in the forma-
tion of protein-protein interactions. This LRR includes GPIb-IX-V complex (see 
Section 2) and TLRs (see Section 13) of platelets. Though these receptors have 
their own class, they also have similarities or common factors between them 
(Table 1).
16. Complement receptors
Several types of complement receptors (CRs) are also expressed by the platelets 
(e.g., CR2, CR3, CR4, C3aR, C5aR, gC1qR, and cC1qR) [77]. These complements 
act as receptor for pathogens (Table 2) and implement multiple functions with both 
direct and indirect antimicrobial host defense (including cell lysis, opsonization, 
and chemotaxis) [69].
17. DC-SIGN
Recently, it has been found that the platelet granules can express the dendritic 
cell-specific ICAM3-grabbing non-integrin (DC-SIGN) receptor (Figure 1 and 
Table 2), like other cells which are used for the interaction with HIV-1 [78]. Platelet 
surface DC-SIGN receptors or enhancement of the receptor FcγII play an important 
role in binding of platelets with Dengue virus (DENV). DC-SIGN and heparin 
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sulfate proteoglycan are receptors for DENV [69]. DENV infection leads to throm-
bocytopenia by increasing phagocytosis of DENV-induced platelets apoptosis by 
macrophages via a phosphatidylserine-recognizing pathway [69].
This detailed description of different platelet receptors will help us to under-
stand the molecular changes of platelet receptors in different conditions.
18. Molecular changes of platelet receptors in different conditions
18.1 During platelet storage
In the cases of thrombocytopenia and bleeding complications, transfusion of 
platelet concentrates (PCs) is one of the most important therapeutic approaches 
and its management formula. Regardless of preparation techniques, stored plate-
lets gradually experience inevitable deleterious changes called as platelet storage 
lesion (PSL). It may lead to a progressive structural and functional damage of 
platelet adhesion receptors from the time of platelets isolation till the transfusion 
to a recipient. It is induced mainly by either reversible or irreversible increases in 
the basal levels of platelet activation, and with the irreversible changes in platelet 
morphology and function the most important phase of PSL is associated with. 
These changes of platelet are significantly initiated with platelet α granules release 
(as mentioned in Sections 11 and 12) and its conversion from pro-aggregatory 
status to pro-inflammatory phenotypes which is identified by the P-selectin and 
CD40L expression [86]. The platelet activation increases the intracellular Ca2+ 
levels and acts as the main modulator of signaling events. This results in platelet 
receptor ectodomain shedding and membrane loss due to microparticulation. 
Both of these phenomena (ectodomain shedding and membrane loss) can cause 
progressive loss of platelet adhesive receptors during platelet storage [4, 87] and 
may affect its proper function required for therapeutic uses. During the storage 
of platelet concentrates (PCs), the GPIbα expression levels have been found to 
be decreased [77, 78]. The continuous shedding can lead to a significant decrease 
in GPIbα expression in 5-day-stored platelets [86]. More old platelets with the 
lower GPIbα expression may show less functionality after transfusion. The 
metalloproteinase-dependent loss of surface GPIbα plays a role in the clearance 
of aged platelets from the circulation. In older PCs, these receptors with higher 
levels of shedding could also be associated with a rapid clearance of transfused 
platelets leading to reduced platelet recovery and survival. In addition to this, the 
GPVI receptor expression also showed to be modulated during storage. A negative 
correlation between GPVI expression and shedding was also observed, a finding 
that verifies the main role of ectodomain shedding in the modulation of GPVI 
expression. There is a direct correlation between the shedding levels of P-selectin 
and GPVI during platelet storage. It suggests that this adhesion receptor is a valid 
marker of PSL [87]. The levels of soluble GPVI have been correlated with soluble 
P-selectin in patients with acute coronary syndrome and/or with acute ischemic 
stroke [88]. Considerable shedding of GPVI and its association with decreasing 
expression of this receptor on the surface of stored platelets can affect GPVI-
dependent platelet function during storage. There is a direct correlation between 
this observed decreased adhesive capacity with the increasing levels of GPVI 
shedding during storage [4].
This enucleated blood component (platelet) may have a chance to interact 
with or interacts definitely under different pathophysiological conditions. Now, 
we will focus on those pathophysiological changes in relation to the platelet 
receptors.
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18.2 During different pathophysiology
18.2.1 Inflammation
Platelets do not only play a role in thrombus formation but are also important in 
atherogenesis, and deficiency of an individual receptor or ligand has been found to 
be compensated by other receptors [89–92]. The inhibition of platelet adhesion in 
atherosclerosis-prone mice impedes the development of atherogenesis in it (these 
models of study) [93]. Platelet adhesion receptors discussed above in the context 
of thrombosis also support interactions between platelets, endothelial cells, and 
leukocytes involved in other vascular processes [94, 95]. Activated platelets with a 
potential mechanism adhered (by GPIbα binding) to the vessel wall with the sup-
port of leukocyte adhesion (with integrin, αMβ2). The GPIbα-binding site of the 
GPIb-IX-V complex similarly involves in the insertion of αM I domain of the αMβ2 
to the vWF, homologous to the vWF-A1 domain [8]. Another mechanism involved 
here is the interaction between the platelet P-selectin and leukocyte PSGL-1 bind-
ing, as mentioned previously [9], and finally, a link between platelets and endothe-
lial cells forms by the fibrinogen or vWF via the engagement of integrins on both 
platelets (such as αIIbβ3) and endothelium (such as αvβ3) [96]. Understanding of 
the involvement of the networking of these platelet-specific receptors in thrombosis 
pathophysiology in vivo is yet to confirm.
18.2.2 Bernard-Soulier syndrome
The Bernard-Soulier syndrome (BSS) is the defect in the three GPIb encod-
ing genes (as mentioned earlier), which gives rise to a serious bleeding diathesis, 
accompanied by anomalies in platelet morphologies, especially giant platelets. It is 
a rare hereditary thrombocytopathy, first described in 1948 by Jean Bernard and 
Jean-Pierre Soulier, two French hematologists, in a young male patient who had 
severe mucocutaneous bleeding, prolonged bleeding time with normal platelet 
count, and abnormally large platelets (macrothrombocytopenia) [90]. In view of 
these defects, the disorder was named as “Dystrophie thrombocytaire-hémorra-
gipare congénitale” (hemorrhagiparous thrombocytic dystrophy) [97]. In most 
cases, bleeding symptoms manifest rapidly after birth or during early childhood. 
Clinical manifestations usually include purpura, epistaxis, gingival bleeding and 
menorrhagia (menstrual periods with abnormally heavy or prolonged bleeding), 
and more rarely gastrointestinal bleeding and hematuria (presence of blood in a 
person’s urine). Severe bleeding episodes are associated with trauma and surgical 
procedures (e.g., tonsillectomy, appendectomy, splenectomy, during dental extrac-
tions), gastric ulcers, and menses. However, indeed the severity and frequency of 
bleeding vary between individuals [21]. Ultrastructural studies of affected platelets 
show a dilated open canalicular system, prominent dense tubular system, and 
vacuolization. It is rare with a reported prevalence of 1 in 1,000,000. Patients have 
a prolonged bleeding time, thrombocytopenia, and larger platelets than the normal 
individual due to defective thrombopoiesis in GPIb defective megakaryocytes [98]. 
Few mutations were reported that cause a gain-of-function in the GPIbα chain, 
leading to the so-called platelet-type GPIB [99], showing a phenotype similar to 
that of certain subtypes of von Willebrand disease [100]. The syndrome, as an 
autosomal recessive trait, is found to be transmitted with an underlying defect of 
deficiency or dysfunction of the GPIb-V-IX complex, required for normal primary 
hemostasis. The GPIb-V-IX complex binds to vWF, allowing platelet adhesion and 
platelet plug formation at sites of vascular injury (as mentioned in Section 2.1) 
(Table 1) [21].
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18.3 Aging and aging-related pathophysiogical conditions
During aging, the platelet receptor expression levels have also been investi-
gated and found that the platelet responsiveness to collagen decreases with age 
with an aging-dependent decrease in GPVI-dependent platelet activation [101]. 
Adhesion receptor levels on nucleated thrombocytes have also been found to 
decrease during aging in correlation with the decrease in participation in throm-
bus formation. The younger thrombocytes contain more adhesive receptors with 
a higher propensity to form the thrombi than the aging counterpart [102]. The 
mechanism of platelet shedding in regulation of aging-related changes in adhe-
sion receptor levels has not been demonstrated yet [103]. Aging with the different 
biochemical alterations due to alteration in cellular microenvironments positively 
associates with the downregulation of different receptors, its consequent signal-
ing pathways, biochemical cascade mechanisms, formation of abnormal proteins, 
its related neurodegeneration, immunosuppression, susceptibility to viral infec-
tion (e.g., COVID-19), etc. and negatively associates with the survival from the 
diseased condition.
18.3.1 Thromboxane alterations
Thromboxane (A2 and B2) is produced from arachidonic acid through endo-
peroxidase by the cyclooxygenase and thromboxane synthase enzyme activity, 
respectively [104]. It plays a pivotal role in platelet aggregation in vivo. It has been 
found that thromboxane production is enhanced in diabetic subjects resulting 
in platelet aggregation, which further provides a higher risk of cardiovascular 
disease [104]. A number of risk factors have been proposed to elevate CVD risk 
in type 1 diabetes mellitus (T1DM) patients, including hyperglycemia, dyslip-
idemia, inflammation, oxidative stress, and genes among others. A significant 
contributing factor to the diabetic prothrombotic state is the aberrant regulation 
of antiplatelet-activating mechanisms that normally maintain high levels of 
inhibitory cAMP to prevent aggregation. Molecules directly affecting platelet 
cAMP production are the arachidonic acid metabolites TXA2 and prostacyclin 
(PGI2). TXA2 is produced in the platelets themselves and is a positive-feedback 
mediator of platelet activation, while PGI2 is produced in endothelial cells and is 
an inhibitor of platelet aggregation. The platelet activator TXA2 is synthesized by 
cyclooxygenase 1 (COX-1) in the platelets; the inhibition of COX-1 (with aspirin), 
which is irreversible and semi-selective, could improve platelet reactivity of 
T1DM subjects [104].
18.3.2 Cardiovascular diseases
The numbers of platelet GP receptors are found to enhance in cardiovascular 
patients and diabetic subjects. The HbA1c is the useful marker to detect the diabetes 
in individuals. The CD40L on platelets has been found to be correlated with this 
HbA1c concentration, as an upregulation of the CD40-CD40L system has been 
observed in diabetes mellitus [56] along with an increase in GPIa/IIa, GPIIb/IIIa, 
P-selectin (CD62), vWF, and CD63 [105]. Patients with ischemic heart disease and 
depression concomitantly may have increased risk of thrombosis due to abnormal 
platelet activation. Moreover, high vWF may increase the chance of cardiovascular 
disease. Elevated plasma levels of vWF are associated with established cardiovascu-
lar risk factors such as age, smoking, cholesterol, diabetes mellitus, and hyperten-
sion [105, 106]. Moreover, raised levels of vWF are predictive of stroke and vascular 
events among patients with atrial fibrillation [106].
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18.3.3 Neurodegeneration
Platelet dysfunctions associated with aging can be linked to molecular altera-
tions affecting several cellular systems that include cytoskeleton rearrangements, 
signal transduction, vesicular trafficking, and protein degradation. Aging in 
platelets and their age-dependent dysfunctions are of interest when evaluating 
the contribution of aging to the onset of aging-dependent pathologies, such as 
those affecting the nervous system linked to neurodegenerative diseases includ-
ing Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), 
Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) [107, 108].
It is well understood from the above information that the platelets have two 
important types of granules, dense granules and alpha granules. The dense granules 
are loaded with proaggregatory factors (e.g., serotonin, calcium, and ADP), and 
during platelet activation, these granules release their content to the open canalicu-
lar system to be expelled out by the platelet, whereas the alpha granules have many 
hemostatic proteins (e.g., platelet-derived growth factor, vWF, and fibrinogen) 
[108]. Aging-related variations in the expression of specific platelet receptors and 
platelet activators have been reported and exemplified by a decrease in the number 
of receptors for PGI2 potent inhibitor of platelet function and high levels of TXA2 
activator of platelet function in older individuals [109]. Even though the most 
important function of platelets is to prevent bleeding, they also play an important 
function in pathological conditions including neurological and neurodegenerative 
diseases (e.g., PD, schizophrenia, and AD). It is also important that platelets show 
high expression of several proteins associated with the development of AD, such as 
the APP amyloid precursor protein (APP) and tau protein. Additionally, platelets 
express enzymes involved in protein modifications such as glycogen synthase kinase 
3 β (GSK-3β), α-, β-, and γ-secretases. Platelets have been compared with neurons 
because they have many biochemical similarities [108], as they have the storage and 
release capacity of neurotransmitters from platelets such as serotonin, glutamate, 
and dopamine [110, 111] and the expression of neuron-related proteins such as 
NMDA receptors [112]. Together, this makes it interesting to consider the contribu-
tion of platelets to the hallmarks of neurodegeneration.
It is very imperative to note that the brains of cerebral amyloid angiopathy 
(CAA) patients (a disorder characterized by deposits of Aβ40 in cerebral arteries 
and capillaries) is estimated its prevalence in 90–98% of AD patients and this AD 
is present in 30% of individuals without dementia over 60 years old. It is need-
less to mention here that AD is related with the amyloid-beta (Aβ) pathogenesis. 
Aβ40 peptide activates and promotes platelet adhesion and aggregation [113] by 
different receptors such as CD36 and GPIbα, triggering several signal transduction 
pathways involving p38MAPK and COX1 and synthesis of TXA2, which ultimately 
increase Ca2+ levels, activates calpain, and increases Aβ40 peptide secretion [114]. 
The thrombin receptor PAR1 could also have a role in the consequent activation of 
p38 MAPK and cytosolic phospholipase A2 (PLA2), and TXA2 formation. Aβ40 
peptides modify platelet shape change and granule release through activation of the 
small GTPase RhoA and phosphorylation of its downstream effector, myosin light 
chain kinase, involving cytoskeletal reorganization [113]. In platelets, the produc-
tion of Aβ40 peptides also regulates the platelets phosphatidylserine exposure 
which has been found to be involved for further increase in platelet Aβ40 levels. A 
correlation between increased ROS formation in AD platelets and increased oxida-
tive stress in AD patients has been demonstrated [108].
The coagulation cascade plays the critical role in the development of an inflam-
matory response in MS. Platelets are trapped in chronic active demyelinating MS 
lesion. The paralysis and experimental autoimmune encephalomyelitis were found 
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to be ameliorated and reduced after inhibiting (the GPIIb/IIIa blocker, abciximab) 
the main platelets integrin GPIIb/IIIa [115]. A role of thrombin cascade in the 
development of inflammation in MS has also pointed out [116]. This multifunc-
tional cell (platelets) is activated by different endogenous, physiological agonists, 
including ADP, collagen, or thrombin, due to the vast number of receptors present 
on the surface of platelets, as discussed previously. During the vessel wall injury, 
the circulating platelets are found to (a) immobilize immediately, (b) interact with 
the vWF binding to collagen and the glycoprotein GPIb-V-IX complex [117], and 
(c) initiate adhesion of free moving platelets of circulation to the subendothelial 
extracellular matrix. The information about involvement and changes of platelet 
receptors in other aging-induced neurodegenerative disorders is yet to be studied.
18.4 Cancer
The knowledge in the last decade on how tumor cells exploit platelets for 
survival, arrest, and finally extravasation from blood vessels to distant organs has 
tremendously increased [118]. Platelets protect circulating tumor cells (CTCs) 
by encasing tumor cells in a thrombus (Figure 2), protecting them from cytolysis 
by natural killer cells [119]. Tumor cells activate platelets for a stable adhesion 
between platelets and tumor cells by distinct mechanisms, which are the reasons 
for hypercoagulation and increased risks of thrombosis in cancer patients [107]. 
Tumor cells release soluble mediators such as ADP, TXA2, or high-mobility group 
box 1 (HMGB1), which ligates with Toll-like receptor 4 (TLR4) to instigate local 
platelet activation [120]. The heterogeneous cloaks of platelets and tumor cells 
protect tumor cells from high shear forces in the blood circulation and from attack 
by leukocytes by a pseudonormal phenotype, and allow tumor cells to downregulate 
MHC class I molecules to escape T cell immune surveillance [118]. This finally leads 
to tumor growth and angiogenesis with a deposition of platelets in tumors by the 
engagement of the P-selectin-αIIbβ3-talin complex [121]. This P-selectin binding 
to its ligands can also activate pro-survival kinases, resulting in enhanced tumor 
growth in mice neuroblastoma cells [122]. Platelets, those bind to colorectal cancer 
cells by means of P-selectin in the presence of polymorphonuclear leukocytes, were 
able to activate human microvascular endothelial cells. This in turn is found to 
express inflammatory proteins, e.g., chemokine CCL5 most abundantly [123]. CCL5 
recruited monocytes to the metastatic microenvironment that finally culminated 
in an augmented number of metastatic foci in the lungs. It suggests that platelets 
and platelet-derived P-selectin seem to be crucially involved in cancer immunity 
(Figure 2).
After platelet activation, αIIbβ3 can switch to at least one of the two different 
active ligand-binding states; both differ in their affinity for fibrinogen, which 
indicates the contribution of αIIbβ3 to tumor cell platelet interaction and aggrega-
tion [118, 124]. Hence, integrin αIIbβ3 is for several reasons an attractive target in 
hematogenous cancer cell dissemination. Different kinds of drugs which efficiently 
inhibit integrin αIIbβ3 have been approved for reduction or prevention of throm-
botic cardiovascular events. Furthermore, integrin αIIbβ3 is capable of mediating 
bidirectional signaling [118]. On the one hand, binding of integrin αIIbβ3 to tumor 
cells can finally culminate in platelet activation, while on the other hand, platelet 
activation by, e.g., ADP, TXA2, or thrombin, can transfer αIIbβ3 to an active 
binding state [107]. These inside-out signaling confers the ability to bind several 
ligands (e.g., melanoma cell expressed αѵβ3), which can induce protumorigenic and 
proangiogenic signals [125].
In different types of cancers, for instance in squamous cell carcinoma, 
lung and skin cancer, mesotheliomas, and cancer-associated fibroblasts, an 
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upregulated expression of podoplanin was detected [118, 126], converting an 
epithelial to mesenchymal transition (EMT) in MDCK cells, by increasing cell 
migration, and was associated with tumor invasion [127]. In healthy human 
tissues, podoplanin is expressed in lymphatic endothelial cells, osteocytes, 
keratinocytes, podocytes, and myofibroblasts among many other cell entities 
[128]. Podoplanin deficiency leads to form defective lymphatic vessels and causes 
death due to respiratory failure after birth [129]. Thus, the CLEC-2-podoplanin 
axis is an interesting target in course of hematogenous metastasis (especially for 
those patients with podoplanin-positive tumors), though more study is needed. 
Meanwhile, the tumor cell-induced platelets aggregating effect of the podoplanin 
CLEC-2 interplay has been revealed in several animal models, and by this way, 
different antibodies targeting different epitopes are generated [118, 130]. CLEC-2 
ligand responsible for pronounced platelet aggregation and a podoplanin recogni-
tion domain in CLEC-2 was elucidated [131]. Podoplanin contains three platelet 
aggregation-stimulating domains in the extracellular section which is crucial 
for the aggregating function [132]. GPVI cytoplasmic tail is associated through 
a salt bridge with the Fc receptor γ chain (FcRγ), and upon ligand-mediated 
GPVI crosslinking and clustering, ITAM motif in FcRγ chains are unmasked 
and phosphorylated. This phosphorylated ITAM is sequentially found to recruit 
and activate Syk downstream signaling complex (composed of LAT and SLP76) 
to activate platelet and spreading of this platelet activation [133]. However, 
the study on the role of this ITAM-containing receptor in the interaction of 
platelets with tumor cells is very limited. Indeed, it has been observed that in 
C57BL/6J mice, deficiency in GPVI leads to decrease in thrombus formation 
with a prolongation of bleeding time [134]. Furthermore, an IgG-independent 
FcγRIIa-mediated cooperation between GPVI, GPIb-IX-V, and αIIbβ3 for platelet 
activation and spreading has been suggested. Studies dealing with the participa-
tion of FcγRIIa in tumor metastasis are barely available [135].
Figure 2. 
Role of platelets in the metastatic cascade. Cells from the primary tumors are detached and invaded into the 
blood circulation. Platelets are activated immediately by their invasion and encasing the invaded tumor cells. 
These activated platelets are able to shift tumor cells to the vascular wall on another site of a distant organ 
and got arrested via interaction of P-selectin and PSGL-1 by facilitating tumor cell extravasation to the 
subendothelial matrix by endothelial P2Y2 receptor activation. (This diagram is adopted from Schlesinger 
[118].)
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Figure 3. 
Schematic presentations of clinical courses of major symptoms and outcomes and duration of viral shedding in 
the COVID-19 patients. ICU: intensive care unit; ARDS: acute respiratory distress syndrome; SARS-CoV-2: 
severe acute respiratory syndrome coronavirus 2; and COVID-19: coronavirus disease 2019. (This diagram is 
adopted from Zhou et al. [136].)
18.5 Platelet receptors and viral pathogens
There are different platelet receptors including TLRs, CRs, and DC-SIGN (as 
described in Sections 13, 16, and 17) that facilitate the direct interaction of platelets 
with viral pathogens. This interaction through different receptors causes both 
quantitative and qualitative dysfunctions of platelets associated with viral patho-
gens (Table 2). Platelets play a role in defending viral pathogen by binding of viral 
pathogen with platelets, which results not only in clearance of platelets but also 
clearance of viral pathogens [69].
18.5.1 Coronavirus disease-2019 (COVID-19)
Recent worldwide outbreak of COVID-19 is known to us as a flu-like disease, 
in which the respiratory illness (like the flu) with symptoms such as cough, fever, 
and in more severe cases, difficulty in breathing occurs. Early during its initiation 
(December, 2019) of infection, it was named as novel coronavirus disease-2019 or 
nCOVID-19. But in the next month (January, 2020), it was named as severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), which was later (February, 
2020) designated as coronavirus disease 2019 or in short “COVID-19” by WHO 
(World Health Organization). Despite of its acute respiratory symptom, it is being 
reported that in more severe cases, abnormal clotting is a common phenomenon 
that culminates into the risk of cardiovascular disease (CVD), and this fact is the 
most crucial one here to discuss with (Figure 3). In severe cases of COVID-19 
patients, clots in the small vessels of all organs, not only in the lungs but also in 
heart, liver, and kidney, have been found [136]. Though the involvement of any 
platelet receptor has not been found yet, the presence of clot indicates toward the 
involvement of platelet receptors for sure, as there are different platelet receptors 
already existing which can bind with different viruses (Table 2). Scientists have 
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noticed till date about the presence of the biomarker of clot, known as D-dimer 
in the blood samples of COVID-19 patients with severity [136]. The presence of 
D-dimer in the circulation has its normal range of <0.5 μg/ml. D-dimers are not 
normally present in human blood plasma, except when the coagulation system 
has been activated (Figure 4). The structure of D-dimer is either a 180- or 195-
kDa molecule of two D domains or a 340-kDa molecule of two D domains and 
one E domain of the original fibrinogen molecule [137]. D-dimer levels over 1 μg/
ml at the time of admission predicted an almost 18-fold increase in odds of dying 
before discharge of nCOVID-19 patients seen at two hospitals in Wuhan, China 
[136]. D-dimer, a fibrin degradation product indicating thrombosis, can exceed 
70 or 80 μg/ml, which clearly can indicate the severity of the illness. In that case, 
the anticoagulation therapy (with the anticoagulation, regardless of the underly-
ing mechanism) may be initiated for severe COVID-19 patients, unless otherwise 
contraindicated the consequences [136].
19. Conclusion
Platelet receptors, particularly their adhesion receptors, execute an important 
role in the regulation of circulatory hemostasis. A rapid transition of circulating rest-
ing platelets to the activated state, adhesion, and aggregation in thrombus formation 
happen by the cascades of events. Briefly, these events are: (i) initial contact adhe-
sion with the platelet GPIb-IX-V and GPVI, and collagen or collagen-bound vWF; 
(ii) activation, spreading, and secretion, involving GPIb-IX-V- and GPVI-dependent 
signaling pathways; (iii) secretion of agonists (e.g., ADP), the P2Y1/P2Y12 recep-
tors activation, and upregulation of integrin αIIbβ3; and (iv) αIIbβ3-dependent 
aggregation, involving vWF or fibrinogen (Table 1 and Figure 1). These processes 
Figure 4. 
Schematic diagram of D-dimer formation as a risk factor for the development of CVD in the COVID-19. 
Fibrinogen is made up of one E domain and two D domain, whereas D-dimer has the same number of 
domains but with different structural orientation with cross-linked D domain.
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happen very fast, and to imagine their rate of reactions, it may be informed that the 
initiation of thrombus formation starts within seconds after an injury, and complete 
thrombus is formed within minutes. Consequent to the aggregation process by 
recruiting free flowing inactivated platelets, the coagulation process accelerates on 
the activated platelet surface with the involvement of leukocytes and RBCs (red 
clot), followed by stabilization of the thrombus with the polymerized fibrin, and 
finally the αIIbβ3-mediated clot contraction in vivo. The dysfunction of GPIb-IX-V 
in humans (Bernard-Soulier syndrome) or mice (GPIbα gene knockouts) throm-
bus formation under high shear conditions is specifically impaired [5, 6]. Recent 
evidence also reveals a requirement for GPVI in stable thrombus formation at high 
shear rates, which provides the evidence of functional co-association of GPVI and 
GPIb-IX-V [6, 25]. The recent discovery of 5-HT receptors (2A and 3) and their role 
on platelet aggregation added a special attention on the interaction of neurotrans-
mitter with the platelet adhesion receptors (Table 1), which may open a new avenue 
in geriatrics research. New molecular insights into the role of primary platelet 
adhesion receptors in vascular biology would be beneficial in pathophysiology study. 
GPIb-IX-V and GPVI together form a multifunctional adhesive cluster of proteins 
on the platelet surface that control thrombus formation at high shear and are also 
central to other vascular processes including inflammation and atherogenesis. Other 
platelet receptors including GPs, integrins, GPCRs, and Ig superfamily also play a 
pivotal role to maintain normal physiology. The physiology and pathophysiology 
of different platelet surface receptors at the molecular level have been described in 
this chapter. The molecular pathophysiology of different platelet receptors under 
different pathological conditions has been described. The recent advancement of the 
knowledge of how platelet is being considered as a biomarker of neurodegeneration 
and how far it is reliable to consider it (platelet) with central nervous system (CNS) 
has been pointed out with its updated information. The molecular aspects of inflam-
mation, cancer (Figure 2), and even viral pathogens (Table 2), especially COVID-19 
pathology (Figures 3 and 4) in relation to platelet receptors, are also taken under 
consideration to present in this chapter. This updated information will enlighten and 
motivate researchers to advance and carry forward their research with platelet at the 
molecular level of its receptor in different pathophysiological conditions. Finally, it 
may be stated that all of these information and thoughts may help to find out differ-
ent biomarkers and treatment for different diseases in the near future.
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